Compostions and method of use for h5 competent bifidobacterium longum subsp. infantis
AssigneeEvolve Biosystems Inc
InventorSteven FRESE
Life of this patent
Estimating the term…
Abstract
Bifidobacterium longum subsp. infantis comprising a functional H5 cluster, including the Bifidobacterium longum subsp. infantis EVC001 deposited under ATCC Accession No. PTA-125180 may be used in compositions for improving gut health in infants and adults.
Claims37
A composition comprising a Bifidobacterium longum subsp. infantis comprising a functional H5 gene cluster and at least one oligosaccharide having a Type I or Type II core.
3-4. (canceled)
(canceled)
8-11. (canceled)
13-18. (canceled)
20-21. (canceled)
23-33. (canceled)
35-36. (canceled)
38-47. (canceled)
49-57. (canceled)
59-77. (canceled)
A method of improving health of a mammalian gastrointestinal tract comprising administering to a mammal in need thereof a therapeutically effective amount of Bifidobacterium longum subsp. infantis having a functional H5 gene cluster and an oligosaccharide having a Type I or Type II core.
81-95. (canceled)
97-101. (canceled)
103-105. (canceled)
107-117. (canceled)
119-127. (canceled)
129-130. (canceled)
A method of preparing activated Bifidobacterium longum subsp. infantis, comprising
- preparing activated Bifidobacterium longum subsp. infantis by cultivating Bifidobacterium by incubating the Bifidobacterium longum subsp. infantis comprising a functional H5 cluster, including the Bifidobacterium longum subsp. infantis EVC001 deposited under ATCC Accession No. PTA-125180, bacteria under conditions whereby gene Blon_0042 is upregulated, gene Blon_2168 is downregulated, or combinations thereof;
- or
- preparing activated Bifidobacterium longum subsp. infantis by cultivating Bifidobacterium by incubating the Bifidobacterium longum subsp. infantis comprising a functional H5 cluster, including the Bifidobacterium longum subsp. infantis EVC001 deposited under ATCC Accession No. PTA-125180, bacteria under conditions whereby one or more of the genes Blon_0042, Blon_0881, Blon_2175, Blon_2176, Blon_2177, Blon_2331, Blon_2334, Blon_2335, Blon_2336, Blon_2337, Blon_2338, Blon_2339, Blon_2343, Blon_2344, Blon_2346, and Blon_2347 is upregulated, and/or Blon_2168 is downregulated;
- or
- preparing activated commensal Bifidobacterium longum subsp. infantis EVC001 deposited under ATCC Accession No. PTA-125180 by culturing said bacterial sp. in presence of a mammalian milk oligosaccharide (MMO) or an activator selected from compounds listed in Table 4, whereby bacterial cells in the culture medium are activated, and
- wherein the MMO or the activator from Table 4 is added in an amount sufficient to induce expression of a gene and/or a protein encoding for a sialidase, a fucosidase, or an alpha-N-acetylgalactosaminidase, or genes listed in Table 1 or Table 2 in bacterial cells, or
- wherein a starting media composition comprises one or more activators from Table 4 in an amount from 0.1 to 3% by weight/vol of the starting media composition, or wherein the MMO and/or the activator constitutes a carbon source and consumption of the carbon source by Bifidobacterium longum subsp. infantis cells both increases cellular biomass and activates a transport system capable of internalizing one or more oligosaccharides before the oligosaccharide is hydrolyzed and consequently the Bifidobacterium longum subsp. infantis cells are further capable of hydrolyzing the oligosaccharide, wherein the oligosaccharide has the structure of an oligosaccharide found in a mammalian milk, and
- wherein the mammalian milk is human, bovine, pig, rabbit, goat, sheep, camel, buffalo milk, or mixtures thereof, or
- wherein the activated bacterial cells have a higher binding affinity to mammalian mucosal cells than bacterial cells of the same species cultivated on non-activating monomers or dimers, or
- wherein activation of the bacterial cells comprises upregulating Blon_0881 and Blon_2343 in Bifidobacterium longum subsp. infantis or functional homologs in other bacterial species, the homologs being expressed during activation of other bacterial species, or
- wherein activation comprises upregulating expression of glucosamine-6-phosphate isomerase and carbohydrate ABC transporter membrane protein from Bifidobacterium longum subsp. infantis, or
- wherein activation of Bifidobacterium cells comprises upregulating genes selected from the group consisting of Blon_0042, Blon_R0015, Blon_R0017, Blon_R0021, Blon_R0022, Blon_2177, and combinations thereof, and/or downregulating genes selected from the group consisting of Blon_0518, Blon_0785, Blon_2167, Blon_2168 from Bifidobacterium longum subsp. infantis, or
- wherein Bifidobacterium cells comprise an upregulated Blon_0042 gene from Bifidobacterium longum subsp. infantis, or
- wherein Bifidobacterium cells comprise a downregulated Blon_2168 and/or Blon_2177 gene from Bifidobacterium longum subsp. infantis, or
- wherein activation of Bifidobacterium cells comprise upregulating genes selected from the group consisting of Blon_0882, Blon_0881, Blon_0880, Blon_0879, Blon_2334, Blon_2335, Blon_2336, Blon_2337, Blon_2338, Blon_2339, Blon_2344, Blon_2346, Blon_2347, Blon_2331, and combinations thereof.
132-144. (canceled)
Dependencies are inferred from the claim text.